After more than a decade of research, a new-generation CAR-T therapy developed by VHIO, in collaboration with the Hospital del…
AECC
Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational next-generation CD19-directed CAR-T cell therapy…
From November 6 to 7, 2025, VHIO hosted the first SOSCLC-AECC Annual Symposium at the “Pabellón Docente” of the Vall d’Hebron Campus. The event brought…
Following the success of its inaugural edition, the Vall d’Hebron Institute of Oncology (VHIO), in partnership with the BBVA Foundation,…
The p95HER2 protein is found expressed in one third of HER2+ tumors, which represent 4% of all tumors. Led by…
Now published in Annals of Oncology (1), updated meta-analysis provides insights into the efficacy of adoptive cell therapy with tumor-infiltrating…
Results of a preclinical, proof-of-concept study led by VHIO’s Stem Cells and Cancer Group demonstrate for the first time the…
VHIO consolidates its advanced therapy programme to develop new innovative treatments against cancer
The 1st VHIO-BBVA Foundation International Symposium on Cell-based Therapies in Oncology , organised by Dr. Alena Gros, head of the…
